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PRELIMINARY AND SHORT REPORTS
ThE TREATMENT OF LUPUS ERYTHEMATOSUS WITH CALCIUM
PANTOTHENATE AND PANTHENOL*
THOMAS COCHRANE, B.Sc., M.D. AND GEORGE LEsLIE, M.D.
It is with interest that we noted the report by Goldman (1) of satisfactory improvement
of subacute and chronic discoid lupus erythematosus under massive calcium pantothenate
therapy. As the successful treatment of lupus erythematosus is still one of the difficult
TABLE 1
Chronic discoid lupus erythematosus treated with calcium pantothenate
problems in dermatology we decided that this method of therapy was worth further investi-
gation. The results of treatment in 28 cases of chronic discoid lupus erythematosus and 9
eases of subacute lupus erythematosus are summarized in Tables 1 and 2.
During the treatment of these cases Wrigley (2) brought to our notice panthenol, the
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alcohol of pantothenic acid, and kindly offered to supply a quantity of this substance to us
for experimental use. Because of the high cost of panthenol in Britain, the quantity given
to us was of necessity small, and only 9 cases of lupus erythematosus could be treated. The
results are summarized in Table 3. During the treatment of these cases Goldman (3) pub-
lished a series of cases treated with panthenol.
TABLE 2
Subacute disseminate tupus erythematosus treated with calcium pantothenate
NO. AGE DISTRIBUTION DURATIONIN YEARS
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TREATMENT
DAILY DOSAGE
(MOM)
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OP THERAPY
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RESULT
Much worse1 66 Generalized 30 B.G.M.S. 300, 100, 200 6
2 18 Generalized 1 B. 400 12 Unchanged
3 36 Generalized 12 B.M. 400 12 Unchanged
4 41 Generalized °TE Nil 400 12 Unchanged
5 33 Generalized 9 B.M. 400, 600 12 Unchanged
6 31 Generalized 3 M. 300, 400, 600 24 Worse
7 36 Generalized 1 S. 400 12 Unchanged
B: Bismuth. G: Gold. M: Mapharside. S: Sulfonamides.
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Chronic discoid and subacute disseminate lupus erythematosus treated with pant henol
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DISCUSSION
It is evident from Tables 1 and 2 that the promising preliminary results of massive
calcium pantothenate in both subacute and chronic discoid lupus erythematosus were not
maintained in the present series of cases. The drug does not compare favorably with the
usual methods of treatment of the disease. This is of interest as 10 cases had scalp lesions
and it was in just such cases that calcium pantothenate was thought to be of value.
It was hoped that panthenol might do what calcium pantothenate had failed to accom-
plish in our hands. The results of Goldman (3) suggest that panthenol is a more efficacious
drug than calcium pantothenate (in 37 cases of subacute and chronic discoid lupus cry-
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thematosis he had success in 30). In addition to panthenol Goldman used various topical
forms of treatment.
In the present series of 9 cases, 6 had received previous treatment with calcium panto-
thenate. No case showed improvement during or after treatment. Unlike Goldman we used
no other treatment. Due to our completely negative results and to the cost of panthenol
in Britain no further clinical trials have been undertaken.
As our results differ so greatly from those of Goldman, we are presenting them in the hope
that they may stimulate further trial of the drugs and so clear the discrepancy which
exists at present.
SUMMARY
Thirty-seven cases of subacute and chronic discoid lupus erythematosus were treated
with massive doses of calcium pantothenate. Nine eases of lupus erythematosus were treated
with panthenol. No improvement was observed in either series.
The drugs compare unfavorably with the standard methods of treatment and the results
suggest that further experimental trials are necessary.
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ANNOUNCEMENT OF AN AFFILIATION BETWEEN THE SKIN AND CANCER
HOSPITAL
AND THE GRADUATE SCHOOL OF MEDICINE OF THE UNIVERSITY OF
PENNSYLVANIA
Mr. Morton Jenks, President of the Board of Trustees, of the Skin and Cancer Hospital
and Mr. William H. DuBarry, Acting President of the University of Pennsylvania announce
the establishment of a medical affiliation between the Skin and Cancer Hospital and the
Graduate School of Medicine.
The Skin and Cancer Hospital will retain its corporative identity. The Graduate School
of Medicine will be responsible for the professional and educational standards of the in-
stitution.
A new Medical Board has been created which will act also as the Executive Committee
of the Medical Staff. This consists of six chiefs of service with the title of Attending Der-
matologists, namely: Drs. Donald M. Pillsbury, Carroll S. Wright, H. E. Twining, Reuben
Friedman, H. M. Samitz, and Edward Ozellers. The Medical Board includes aso Dr. Herman
Beerman, Chairman of the Department of Dermatology and Syphilology, Graduate School
of Medicine, and Dr. Bertram Shaffer, Medical Director. Dr. Pillsbury will be the Chairman
of the Medical Board.
Under this new arrangement, the hospital will be staffed by dermatologists from insti-
tutions throughout the city and it will participate in graduate teaching in dermatology of
residents and fellows associated with these institutions.
